Cargando…

Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment

INTRODUCTION: In the present study, we sought to identify markers in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that distinguish those achieving remission at 6 months following rituximab or cyclophosphamide treatment from those for whom treatment failed in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasrallah, Mazen, Pouliot, Yannick, Hartmann, Bjoern, Dunn, Patrick, Thomson, Elizabeth, Wiser, Jeffrey, Butte, Atul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576403/ https://www.ncbi.nlm.nih.gov/pubmed/26387933 http://dx.doi.org/10.1186/s13075-015-0778-z

Ejemplares similares

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis
por: Agosto‐Burgos, Christian, et al.
Publicado: (2022)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies
por: Ui Mhaonaigh, Aisling, et al.
Publicado: (2019)

Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab
por: Khan, Afsha, et al.
Publicado: (2010)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Prevalence of large vessel vasculitis in ANCA-associated vasculitis: a retrospective cohort study
por: Coattrenec, Yann, et al.
Publicado: (2021)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

ANCA‐associated vasculitis with scleritis, corneal melt, and perforation rescued by rituximab: Case report and literature review
por: Matsuo, Toshihiko, et al.
Publicado: (2023)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
por: Sagmeister, Michael S., et al.
Publicado: (2018)

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
por: Caroti, L., et al.
Publicado: (2019)

Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohort
por: Carranza-Enríquez, Fabián, et al.
Publicado: (2022)

Progress in treatment of ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2012)

Animal Models of ANCA Associated Vasculitis
por: Shochet, Lani, et al.
Publicado: (2020)

Eye involvement in ANCA positive vasculitis
por: Macarie, Sorin Simion, et al.
Publicado: (2020)

Mechanisms of thrombosis in ANCA-associated vasculitis
por: Misra, Durga Prasanna, et al.
Publicado: (2021)

Granulomatous Inflammation in ANCA-Associated Vasculitis
por: Müller, Antje, et al.
Publicado: (2021)

Complement Inhibition in ANCA-Associated Vasculitis
por: Tesar, Vladimir, et al.
Publicado: (2022)

The involvement of NETs in ANCA-associated vasculitis
por: Shiratori-Aso, Satoka, et al.
Publicado: (2023)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
por: Thiel, Jens, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fi0e2ji9sevhdt5lc8fdu0jtkk